Advances in Cancer Treatment: Lipid-Based Nanoparticles Offer New Hope

Strategic Insights -

Researchers at the University of British Columbia have made significant progress in the field of cancer treatment, revealing that nearly half of humanity will develop cancer in their lifetime. Current therapies, particularly chemotherapeutic drugs, face significant challenges due to the lack of tissue-specific delivery. To address this issue, lipid-based nanoparticles (LBNPs) have been developed, which can enhance a drug's circulation half-life in the bloodstream and exploit the enhanced permeability and retention (EPR) effect.

Key Takeaways:

  • Nearly half of humanity will develop cancer in their lifetime, making cancer a significant global health concern.
  • Current chemotherapeutic drugs face significant challenges due to the lack of tissue-specific delivery, resulting in damage to healthy tissues and a wide range of side effects.
  • Lipid-based nanoparticles (LBNPs) offer a promising solution to address the problem of tissue-specific delivery, with more than 20 FDA-approved chemotherapeutic drugs approved for use.
  • LBNPs have improved pharmacokinetics, enabling a higher maximum tolerated dose while maintaining similar therapeutic efficacy and reducing side effects.
  • However, a key limitation of LBNPs is their stability, which can limit anticancer efficacy.
  • Externally triggered release strategies, such as thermal, ultrasound, radiation, magnetic, and light-based approaches, offer a potential solution to overcome the stability barrier and enable higher tumor-specific drug concentrations with fewer systemic side effects.
  • This article reviews recent advances in externally triggered release mechanisms for LBNPs and examines their potential integration into clinical cancer settings.
  • Abdulaziz Alhussan, Louise Ho, Yao Zhang, Harrison Fan, Arash Momeni, Cedric Brimacombe, and Pieter R. Cullis are among the researchers who contributed to this study.
  • The research was published in the Journal of Nanobiotechnology, a peer-reviewed journal issued by BioMed Central.

Statistics:

  • Nearly half of humanity (47.8%) will develop cancer in their lifetime (1).
  • Less than 0.1% of anticancer drugs administered systemically reach the tumor site, resulting in damage to healthy tissues and a wide range of side effects (2).
  • More than 20 FDA-approved chemotherapeutic drugs have been approved for use with lipid-based nanoparticles (LBNPs) (3).
  • Lipid-based nanoparticles (LBNPs) offer improved pharmacokinetics, enabling a higher maximum tolerated dose while maintaining similar therapeutic efficacy and reducing side effects (4).
  • Externally triggered release strategies, such as thermal, ultrasound, radiation, magnetic, and light-based approaches, offer a potential solution to overcome the stability barrier and enable higher tumor-specific drug concentrations with fewer systemic side effects (5).

Sources:

  • NewsRx. New Findings from University of British Columbia in the Area of Cancer Reported (Lipid-based nanoparticles external triggered release strategies in cancer nanomedicine). Cancer Weekly. October 21, 2025; p 1195.
  • Lipid-based nanoparticles external triggered release strategies in cancer nanomedicine. Journal of Nanobiotechnology, 2025;23(1):641. Journal of Nanobiotechnology can be contacted at: Bmc, Campus, 4 Crinan St, London N1 9XW, England. (BioMed Central - www.biomedcentral.com/; Journal of Nanobiotechnology - www.jnanobiotechnology.com)